Hasil Pencarian - Michel Delforge

Perbaiki Hasil
  1. 1
    Multiple myeloma

    Multiple myeloma oleh Michel Delforge

    Diterbitkan 2018-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    CURRENT DEVELOPMENTS AND PERSPECTIVES IN MULTIPLE MYELOMA

    CURRENT DEVELOPMENTS AND PERSPECTIVES IN MULTIPLE MYELOMA oleh Michel Delforge, Stefan Knop, Mohamad Mohty

    Diterbitkan 2014-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Two Cases of Heavy Chain MGUS

    Two Cases of Heavy Chain MGUS oleh Jan Van Keer, Björn Meijers, Michel Delforge, Gregor Verhoef, Koen Poesen

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma

    Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma oleh Jan Van Keer, Michel Delforge, Daan Dierickx, Kathelijne Peerlinck, Evelyne Lerut, Ben Sprangers

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Case report: Chronic neutrophilic leukemia associated with monoclonal gammopathies. A case series and review of genetic characteristics and practical management

    Case report: Chronic neutrophilic leukemia associated with monoclonal gammopathies. A case series and review of genetic characteristics and practical management oleh Gaël Vermeersch, Michel Delforge, Violaine Havelange, Carlos Graux, Lucienne Michaux, Timothy Devos, Timothy Devos

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients

    Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients oleh Ben Sprangers, Kathleen Claes, Pieter Evenepoel, Dirk Kuypers, Koen Poesen, Michel Delforge, Xavier Bossuyt V, Björn Meijers

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

    Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or... oleh Meletios A. Dimopoulos, Michel Delforge, Roman Hájek, Martin Kropff, Maria T. Petrucci, Philip Lewis, Annabel Nixon, Jingshan Zhang, Jay Mei, Antonio Palumbo

    Diterbitkan 2013-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review

    Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review oleh Roman Hájek, Sebastian Gonzalez-McQuire, Zsolt Szabo, Michel Delforge, Lucy DeCosta, Marc S Raab, Walter Bouwmeester, Marco Campioni, Andrew Briggs

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    A double-edged sword

    A double-edged sword oleh Martijn Vandebotermet, Frederik Staels, Simone Giovannozzi, Michel Delforge, Thomas Tousseyn, Thomas Steelandt, Anniek Corveleyn, Isabelle Meyts, Johan Maertens, Jonas Yserbyt, Rik Schrijvers

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

    Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group oleh Frédéric Baron, Stefan Suciu, Sergio Amadori, Petra Muus, Heinz Zwierzina, Claudio Denzlinger, Michel Delforge, Antoine Thyss, Dominik Selleslag, Karel Indrak, Gert Ossenkoppele, Theo de Witte

    Diterbitkan 2012-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma

    Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma oleh Isabel J.F. Hofman, Stephanie Patchett, Mark van Duin, Ellen Geerdens, Jelle Verbeeck, Lucienne Michaux, Michel Delforge, Pieter Sonneveld, Arlen W. Johnson, Kim De Keersmaecker

    Diterbitkan 2017-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Ultra-low coverage whole genome sequencing of ccfDNA in multiple myeloma: A tool for laboratory routine?

    Ultra-low coverage whole genome sequencing of ccfDNA in multiple myeloma: A tool for laboratory routine? oleh Laura Yissel Rengifo, Sanne Smits, Lieselot Buedts, Michel Delforge, Luc Dehaspe, Thomas Tousseyn, Nancy Boeckx, Stefan Lehnert, Lucienne Michaux, Joris Robert Vermeesch, Peter Vandenberghe, Barbara Dewaele

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes

    Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes oleh Jasper Edgar Neggers, Bert Kwanten, Tim Dierckx, Hiroki Noguchi, Arnout Voet, Lotte Bral, Kristien Minner, Bob Massant, Nicolas Kint, Michel Delforge, Thomas Vercruysse, Erkan Baloglu, William Senapedis, Maarten Jacquemyn, Dirk Daelemans

    Diterbitkan 2018-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

    Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study oleh Karthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, Michel Delforge, Francesca Gay, Salomon Manier, Joaquín Martinez-Lopez, Maria Victoria Mateos, Mohamad Mohty, Niels W.C.J. van de Donk, Katja Weisel

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma oleh Maria Victoria Mateos, Katja Weisel, Evangelos Terpos, Sossana Delimpasi, Efstathios Kastritis, Elena Zamagni, Michel Delforge, Enrique Ocio, Eirini Katodritou, Francesca Gay, Alessandra Larocca, Xavier Leleu, Paula Rodriguez Otero, Fredik Schjesvold, Michele Cavo, Meletios A. Dimopoulos

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

    Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network oleh Philippe Moreau, Pieter Sonneveld, Mario Boccadoro, Gordon Cook, Ma Victoria Mateos, Hareth Nahi, Hartmut Goldschmidt, Meletios A. Dimopoulos, Paulo Lucio, Joan Bladé, Michel Delforge, Roman Hajek, Heinz Ludwig, Thierry Facon, Jesus F. San Miguel, Hermann Einsele

    Diterbitkan 2019-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice

    Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice oleh Michel Delforge, Marie-Christiane Vekemans, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Vande Broek, Sophie Vandervennet, Sandra Van Hoorenbeeck, Evelien Moorkens, Danielle Strens, Joris Diels, Francesca Ghilotti, Benjamin Haefliger, Sander Dalhuisen, William Deraedt, Sébastien Anguille

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    What matters most to patients with multiple myeloma? A Pan-European patient preference study

    What matters most to patients with multiple myeloma? A Pan-European patient preference study oleh Rosanne Janssens, Tamika Lang, Ana Vallejo, Jayne Galinsky, Kate Morgan, Ananda Plate, Chris De Ronne, Margaux Verschueren, Elise Schoefs, Anneleen Vanhellemont, Michel Delforge, Fredrik Schjesvold, Fredrik Schjesvold, Elena Cabezudo, Martina Vandebroek, Hilde Stevens, Steven Simoens, Isabelle Huys

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma oleh Torben Plesner, Simon J. Harrison, Hang Quach, Cindy Lee, Adam Bryant, Annette Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert Hendricks, Shannon M. Ruppert, Teiko Sumiyoshi, Karen Miller, Eunpi Cho, Fredrik Schjesvold

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS

    P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL)... oleh Michel Delforge, Krina Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas Marshall, Bertrand Arnulf, Michele Cavo, Ajay Nooka, Salomon Manier, Natalie Callander, Sergio Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa Mckiver, Mark Cook, Paula Rodríguez-Otero

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: